Toshifumi Matsui
Research Subjects
Research Interests
Toshifumi Matsui has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Sachio Matsushita
Medical Center for Dementia in Kanagawa Prefecture National Hospital Organization, Kurihama Alcoholism Center Kanagawa Japan
2 shared publicationsAkane Nagata
Medical Center for Dementia in the Northeastern Wards of Tokyo Metropolis Oouchi Hospital, Heisei Medical Welfare Group Tokyo Japan
1 shared publicationAyami Nakazawa
Department of Anatomy II, Fujita Health University School of Medicine, Aichi, Japan
1 shared publicationHidetada Sasaki
Department of Anatomy II, Fujita Health University School of Medicine, Aichi (AN,NU); Department of Geriatric Medicine, Tohoku University School of Medicine, Sendai (TM,HA,HS); National Nagano Hospital, Ueda (TH); and National Institute on Alcoholism, Kurihama National Hospital, Kanagawa (SM,SH), Japan
1 shared publication- Hidetada Sasaki
Sendai Tomizawa Hospital Sendai Japan
1 shared publication - Hiroyuki Arai
The University of Tokyo
1 shared publication
Latest Publications
- 25 January 2023
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 23 (3) , 200-204
Accelerated cognitive decline after the COVID‐19 pandemic in a community population of older persons with cognitive impairment: A 4‐year time series analysis in the Tokyo Metropolis area
Aim: The coronavirus disease 2019 (COVID‐19) pandemic has led to lifestyle restrictions and might be associated with long‐term changes in cognitive function. The aim of the present study was to elucidate the overall effect of the COVID‐19 pandemic on the cognitive trajectory of a cohort of patients with cognitive impairment.Methods: We enrolled 160 patients who had been making regular visits to a medical center for dementia. Cognitive function was assessed based on changes in scores on the Mini‐Mental State Examination before and during the COVID‐19 pandemic throughout a 4‐year period. The trajectory of cognitive decline was determined by carrying out a time series analysis using a state‐space model.Results: Crude analysis showed that the Mini‐Mental State Examination scores decreased from 20.9 ± 4.4 points (mean ± SD) at the time of the initial cognitive assessments to 17.5 ± 5.6 points at the time of the final assessments, and the decline rate was 1.15 ± 1.78 points per year (P < 0.0001). The time series analysis showed an accelerated cognitive trajectory after the COVID‐19 outbreak, and the average decline in the Mini‐Mental State Examination scores was 0.46 points (95% confidence interval 0.034–0.91) per year before the COVID‐19 pandemic, and a steeper decline of 1.87 points (95% confidence interval 1.34–2.67) per year after the outbreak.Conclusions: The COVID‐19 pandemic accelerated the rate of cognitive decline in patients with cognitive impairment fourfold in comparison with before the pandemic. Specific strategies designed for cognitively older people in the “new normal” will reconcile both requirements, reducing the risk of infection, and maintaining their physical and psychological well‐being. Geriatr Gerontol Int 2023; 23: 200–204.
- 25 January 2023
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 23 (3) , 200-204
Accelerated cognitive decline after the COVID‐19 pandemic in a community population of older persons with cognitive impairment: A 4‐year time series analysis in the Tokyo Metropolis area
Aim: The coronavirus disease 2019 (COVID‐19) pandemic has led to lifestyle restrictions and might be associated with long‐term changes in cognitive function. The aim of the present study was to elucidate the overall effect of the COVID‐19 pandemic on the cognitive trajectory of a cohort of patients with cognitive impairment.Methods: We enrolled 160 patients who had been making regular visits to a medical center for dementia. Cognitive function was assessed based on changes in scores on the Mini‐Mental State Examination before and during the COVID‐19 pandemic throughout a 4‐year period. The trajectory of cognitive decline was determined by carrying out a time series analysis using a state‐space model.Results: Crude analysis showed that the Mini‐Mental State Examination scores decreased from 20.9 ± 4.4 points (mean ± SD) at the time of the initial cognitive assessments to 17.5 ± 5.6 points at the time of the final assessments, and the decline rate was 1.15 ± 1.78 points per year (P < 0.0001). The time series analysis showed an accelerated cognitive trajectory after the COVID‐19 outbreak, and the average decline in the Mini‐Mental State Examination scores was 0.46 points (95% confidence interval 0.034–0.91) per year before the COVID‐19 pandemic, and a steeper decline of 1.87 points (95% confidence interval 1.34–2.67) per year after the outbreak.Conclusions: The COVID‐19 pandemic accelerated the rate of cognitive decline in patients with cognitive impairment fourfold in comparison with before the pandemic. Specific strategies designed for cognitively older people in the “new normal” will reconcile both requirements, reducing the risk of infection, and maintaining their physical and psychological well‐being. Geriatr Gerontol Int 2023; 23: 200–204.
- Open Access
- 1 February 2001
- Published by SAGE Publications in Journal of Histochemistry & Cytochemistry
- Vol. 49 (2) , 187-195
Localization of Calcineurin in the Mature and Developing Retina
SUMMARY We studied the localization of calcineurin by immunoblotting analysis and immunohistochemistry as a first step in clarifying the role of calcineurin in the retina. Rat, bovine, and human retinal tissues were examined with subtype-nonspecific and subtype-specific antibodies for the Aα and Aβ isoforms of its catalytic subunit. In mature retinas of the three species, calcineurin was localized mainly in the cell bodies of ganglion cells and the cells in the inner nuclear layer, in which amacrine cells were distinctively positive. The calcineurin Aα and Aβ isoforms were differentially localized in the nucleus and the cytoplasm of the ganglion cell, respectively. Calcineurin was also present in developing rat retinas, in which the ganglion cells were consistently positive for it. The presence of calcineurin across mammalian species and regardless of age shown in the present study may reflect its importance in visual function and retinal development, although its function in the retina has not yet been clarified. (J Histochem Cytochem 49:187–195, 2001)
- 1 February 2001
- Published by SAGE Publications in Journal of Histochemistry & Cytochemistry
- Vol. 49 (2) , 187-195
Open AccessLocalization of Calcineurin in the Mature and Developing Retina
SUMMARY We studied the localization of calcineurin by immunoblotting analysis and immunohistochemistry as a first step in clarifying the role of calcineurin in the retina. Rat, bovine, and human retinal tissues were examined with subtype-nonspecific and subtype-specific antibodies for the Aα and Aβ isoforms of its catalytic subunit. In mature retinas of the three species, calcineurin was localized mainly in the cell bodies of ganglion cells and the cells in the inner nuclear layer, in which amacrine cells were distinctively positive. The calcineurin Aα and Aβ isoforms were differentially localized in the nucleus and the cytoplasm of the ganglion cell, respectively. Calcineurin was also present in developing rat retinas, in which the ganglion cells were consistently positive for it. The presence of calcineurin across mammalian species and regardless of age shown in the present study may reflect its importance in visual function and retinal development, although its function in the retina has not yet been clarified. (J Histochem Cytochem 49:187–195, 2001)
- Open Access
- 1 January 2000
- Published by The Japan Geriatrics Society in Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics
- Vol. 37 (12) , 974-978
Prediction of Progression in Patients with Mild Cognitive Impairment Using IMP-SPECT.
記憶障害が存在するもののその他の認知機能はおおむね正常で, 自立した日常生活が継続できるような段階は, Mild cognitive impairment (MCI) という名称で, 近年定義づけられ, Alzheimer 病 (AD)の発症予備群と考えられている. そこでMCIと正常加齢の脳機能画像上の違いを明らかにする目的で, 19名のMCI患者, 23名のAD患者, 15名の正常高齢者において, IMP-SPECTを用いて局所脳血流の測定を行った. 平均MMSEスコアは, MCI群が25.3±1.2 (mean±SD), AD群が17.5±3.3であった. 後帯状回, 前頭葉, 側頭葉, 頭頂葉に関心領域 (ROI) を設定し, 小脳のROI値に基づいて標準化して, 脳血流比を算出した. また Statistical Parametric Mapping (SPM) を使用して, ボクセル単位での画像比較も行った. その結果, 後帯状回における局所脳血流比は正常高齢者群と比較して, MCI群 (0.956±0.080), AD群 (0.833±0.118) ともに有意に低下していた. その他の領域の局所脳血流比は, AD群と正常高齢者群との間でのみ有意差を認めた. 後帯状回局所脳血流比を用いて正常高齢者とMCI患者を鑑別する場合, 特異度を80%に設定した際の感度は80.5%であった. SPMにより, 正常高齢者とMCI患者の脳血流画像を比較すると, ROI解析と同様に, 後帯状回においてのみ有意差を認めた. 以上の結果から, 後帯状回の脳血流低下を示すMCI患者はADへ進行する危険性が高いことが示唆され, 脳血流画像からMCI患者のADへの進行を予測可能であることが確認された.
- 1 January 2000
- Published by The Japan Geriatrics Society in Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics
- Vol. 37 (12) , 974-978
Open AccessPrediction of Progression in Patients with Mild Cognitive Impairment Using IMP-SPECT.
記憶障害が存在するもののその他の認知機能はおおむね正常で, 自立した日常生活が継続できるような段階は, Mild cognitive impairment (MCI) という名称で, 近年定義づけられ, Alzheimer 病 (AD)の発症予備群と考えられている. そこでMCIと正常加齢の脳機能画像上の違いを明らかにする目的で, 19名のMCI患者, 23名のAD患者, 15名の正常高齢者において, IMP-SPECTを用いて局所脳血流の測定を行った. 平均MMSEスコアは, MCI群が25.3±1.2 (mean±SD), AD群が17.5±3.3であった. 後帯状回, 前頭葉, 側頭葉, 頭頂葉に関心領域 (ROI) を設定し, 小脳のROI値に基づいて標準化して, 脳血流比を算出した. また Statistical Parametric Mapping (SPM) を使用して, ボクセル単位での画像比較も行った. その結果, 後帯状回における局所脳血流比は正常高齢者群と比較して, MCI群 (0.956±0.080), AD群 (0.833±0.118) ともに有意に低下していた. その他の領域の局所脳血流比は, AD群と正常高齢者群との間でのみ有意差を認めた. 後帯状回局所脳血流比を用いて正常高齢者とMCI患者を鑑別する場合, 特異度を80%に設定した際の感度は80.5%であった. SPMにより, 正常高齢者とMCI患者の脳血流画像を比較すると, ROI解析と同様に, 後帯状回においてのみ有意差を認めた. 以上の結果から, 後帯状回の脳血流低下を示すMCI患者はADへ進行する危険性が高いことが示唆され, 脳血流画像からMCI患者のADへの進行を予測可能であることが確認された.